Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)

Title: Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)
Authors: Laura A. Huppert; Reshma Mahtani; Samantha Fisch; Naomi Dempsey; Sarah Premji; Angelina Raimonde; Saya Jacob; Laura Quintal; Michelle Melisko; Jo Chien; Ana Sandoval; Lauren Carcas; Manmeet Ahluwalia; Natasha Harpalani; Jenna Hoppenworth; Anne Blaes; Kelly Blum; Mi-Ok Kim; Dame Idossa; Ruta Rao; Karthik V. Giridhar; Hope S. Rugo
Source: npj Breast Cancer, Vol 11, Iss 1, Pp 1-8 (2025)
Publisher Information: Nature Portfolio
Publication Year: 2025
Collection: Directory of Open Access Journals: DOAJ Articles
Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
Description: Antibody drug conjugates (ADCs) have improved outcomes for patients with metastatic breast cancer (MBC), but there is little data about the sequential use of these agents. In this multicenter retrospective cohort study, we identified 84 patients with HER2-low MBC treated sequentially with trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in either order at 5 institutions between 2020–2024. We evaluated clinical parameters associated with time to treatment failure (TTF) and real-world overall survival (rwOS). Median TTF was longer for ADC1 than ADC2, irrespective of HR-status, ADC sequence order, age ≤65 or >65 years, presence of visceral disease, or use of an intervening therapy. Younger age, longer time from MBC diagnosis to start of ADC1, and receipt of SG as ADC1 were associated with longer rwOS from start of ADC1. This cohort represents one of the first multicenter retrospective series of patients treated with sequential ADCs for HER2-low MBC, which may inform clinical practice.
Document Type: article in journal/newspaper
Language: English
Relation: https://doi.org/10.1038/s41523-025-00748-5; https://doaj.org/toc/2374-4677; https://doaj.org/article/da50fc999b7b4124a831fd4850a6cf0b
DOI: 10.1038/s41523-025-00748-5
Availability: https://doi.org/10.1038/s41523-025-00748-5; https://doaj.org/article/da50fc999b7b4124a831fd4850a6cf0b
Accession Number: edsbas.E480F898
Database: BASE